SEARCH

SEARCH BY CITATION

References

  • 1
    Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 2008;371:2619.
  • 2
    Larroque B, Bréart G, Kaminski M, Dehan M, André M, Burguet A, et al. Survival of very preterm infants: EPIPAGE, a population based cohort study. Arch Dis Child Fetal Neonatal Ed 2004;89:F13944.
  • 3
    Doyle LW, for the Victorian Infant Collaborative Study Group. Outcome at 5 years of age of children 23 to 27 weeks’ gestation: refining the prognosis. Pediatrics 2001;108:13441.
  • 4
    Moster D, Lie RT, Markestad T. Long-term medical and social consequences of preterm birth. N Engl J Med 2008;359:26273.
  • 5
    Ancel P-Y, Livinec F, Larroque B, Marret S, Arnaud C, Pierrat V, et al. Cerebral palsy among very preterm children in relation to gestational age and neonatal ultrasound abnormalities: the EPIPAGE cohort study. Pediatrics 2006;117:82835.
  • 6
    Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995;95:2639.
  • 7
    Kuban KCK, Leviton A, Pagano M, Fenton T, Strassfeld R, Wolff M. Maternal toxemia is associated with reduced incidence of germinal matrix hemorrhage in premature babies. J Child Neurol 1992;7:706.
  • 8
    Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003;290:266976.
  • 9
    Magpie Trial Follow-Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. Br J Obstet Gynaecol 2007;114:28999.
  • 10
    Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Lévêque C, Hellot MF, et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. Br J Obstet Gynaecol 2007;114:3108.
  • 11
    Mittendorf R, Dambrosia J, Pryde PG, Lee K-S, Gianopoulos JG, Besinger RE, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol 2002;186:11118.
  • 12
    Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008;359:895905.
  • 13
    Doyle LW, Crowther CA, Middleton P, Marret S, Rouse DJ. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009;1:CD004661. DOI:10.1002/14651858.CD004661.pub3.
  • 14
    Duley L, Gulmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev 2010;11:CD000025. DOI: 10.1002/14651858.CD000025.pub2.
  • 15
    Duley L, Matar H, Almerie M, Hall D. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Cochrane Database Syst Rev 2010;8:CD007388. DOI: 10.1002/14651858.CD007388.pub2.
  • 16
    Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 2002;4:CD001060. DOI: 10.1002/14651858.CD001060.
  • 17
    Han S, Crowther CA, Moore V. Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev 2010;7:CD000940. DOI: 10.1002/14651858.CD000940.pub2.
  • 18
    Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. Clin Pharmacokinet 2000;38:30514.
  • 19
    McCubbin JH, Sibai BM, Abdella TN, Anderson GD. Cardiopulmonary arrest due to acute maternal hypermagnesaemia. Lancet 1981;317:1058.
  • 20
    Richards A. Cardiopulmonary arrest after the administration of magnesium sulphate. A case report. S Afr Med J 1985;67:145.
  • 21
    Bain E, Middleton P, Crowther C. Different magnesium sulphate regimens for neuroprotection of the fetus for women at risk of preterm birth. Cochrane Database Syst Rev 2012;2:CD009302. DOI: 10.1002/14651858.CD009302.
  • 22
    The Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child: national clinical practice guidelines. Adelaide, SA: The University of Adelaide, 2010.
  • 23
    South Australian Perinatal Practice Guidelines Workgroup. South Australian Perinatal Practice Guidelines. Chapter 96b Magnesium sulphate for neuroprotection of the fetus in women at risk of preterm birth. Adelaide, SA: SA Health, 2010.
  • 24
    Flenady V, King J, Charles A, Gardener G, Ellwood D, Day K, et al. for the Perinatal Society of Australia and New Zealand (PSANZ) Perinatal Mortality Group. PSANZ Clinical Practice Guideline for Perinatal Mortality Version 2.2. Brisbane, QLD: PSANZ Perinatal Mortality Group, 2009.
  • 25
    Loke Y, Price D, Herxheimer A, Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol 2007;7:19.
  • 26
    Bent S, Padula A, Avins AL. Brief communication: better ways to question patients about adverse medical events. Ann Intern Med 2006;144:25761.
  • 27
    Young BK, Weinstein HM. Effects of magnesium sulfate on toxemic patients in labor. Obstet Gynecol 1977;49:6815.
  • 28
    Bain ES, Middleton PF, Crowther CA. Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review. BMC Pregnancy Childbirth 2013;13:195.